Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer

BACKGROUND: Lazertinib is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to overcome EGFR T790M mutation. Currently, lazertinib is approved for usage in the acquired EGFR T790M mutation population based on promising clinical and safety profiles. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sehhoon, Jung, Hyun Ae, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju, Sun, Jong-Mu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579823/
https://www.ncbi.nlm.nih.gov/pubmed/37854157
http://dx.doi.org/10.21037/tlcr-23-160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579823/
https://www.ncbi.nlm.nih.gov/pubmed/37854157
http://dx.doi.org/10.21037/tlcr-23-160

Ejemplares similares